GlassScriptPhysician profile
Yelitza Ruiz
NPI 1952412918
$27,626.95
in general payments reported to CMS, 2019-2025
58 companies · $6,017 in 2025
The $6,017 reported for 2025 was more than what 84% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,033 · 2020: $3,118 · 2021: $4,186 · 2022: $2,341 · 2023: $4,342 · 2024: $4,590 · 2025: $6,017.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Education: $178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,770.84 |
| Education | $177.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $6,006.54 | 2019-2025 | Opdivo, Reblozyl, Opdualag |
| Janssen Pharmaceuticals, INC | $2,168.19 | 2019-2025 | Darzalex, Erleada, Rybrevant |
| Astrazeneca Pharmaceuticals LP | $2,107.35 | 2019-2025 | Enhertu, Calquence, Lynparza |
| Pbg Puerto Rico LLC | $1,855.81 | 2019-2025 | |
| Abbvie INC. | $1,612.15 | 2019-2025 | Venclexta, Lupron Depot, Epkinly |
| Genentech USA, INC. | $1,611.80 | 2019-2025 | Polivy, Lunsumio, Tecentriq |
| Merck Sharp & Dohme LLC | $1,216.67 | 2019-2025 | Keytruda, Keytruda Qlex, Welireg |
| Novartis Pharmaceuticals Corporation | $1,194.97 | 2019-2025 | |
| Amgen INC. | $1,066.15 | 2019-2025 | Xgeva, Kyprolis, Lumakras |
| Eli Lilly Export S.A. Puerto Rico Branch | $1,027.05 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Genzyme Corporation | $677.84 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $512.45 | 2019-2025 | Ninlaro |
| Incyte Corporation | $430.27 | 2019-2025 | Monjuvi, Jakafi, Pemazyre |
| Astellas Pharma US INC | $387.24 | 2023-2025 | Xospata, Padcev, Vyloy |
| Pfizer INC. | $366.01 | 2019-2025 |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $362.87 | 2019-2021 | |
| Janssen Biotech, INC. | $356.45 | 2019-2021 | |
| Bayer Puerto Rico INC. | $347.41 | 2023-2025 | Nubeqa, Stivarga, Vitrakvi |
| Tempus Ai, INC | $335.91 | 2024-2025 | Xt Cdx |
| Puma Biotechnology, INC. | $329.48 | 2019-2025 | |
| Exelixis INC. | $283.69 | 2019-2025 | Cabometyx |
| Glaxosmithkline, LLC. | $281.63 | 2021-2025 | Ojjaara, Zejula, Jemperli |
| Pharmaessentia USA Corporation | $262.71 | 2022-2025 | Besremi |
| Sobi, INC | $244.05 | 2023-2025 | |
| Eisai INC. | $236.01 | 2019-2025 | |
| Adc Therapeutics America, INC. | $213.03 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $200.72 | 2023-2025 | Libtayo, Lynozyfic |
| Taiho Oncology, INC. | $181.04 | 2019-2025 | |
| Beigene USA, INC. | $167.53 | 2020-2024 | Brukinsa |
| Rigel Pharmaceuticals, INC. | $122.08 | 2021-2025 | Rezlidhia, Tavalisse, Gavreto |
| Mirati Therapeutics, INC. | $115.62 | 2023-2024 | Krazati |
| Seagen INC. | $111.79 | 2019-2023 | Tukysa |
| Bayer Healthcare Pharmaceuticals INC. | $105.19 | 2020-2022 | |
| Verity Pharmaceuticals INC. | $94.87 | 2022-2023 | Akynzeo, Trelstar |
| Pfizer Pharmaceuticals LLC | $94.62 | 2019 | |
| Clovis Oncology, INC. | $84.16 | 2020-2022 | |
| Sun Pharmaceutical Industries INC. | $80.19 | 2025 | |
| Jazz Pharmaceuticals INC. | $70.22 | 2022-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $70.14 | 2019-2023 | Imbruvica |
| Tolmar, INC. | $65.11 | 2024-2025 | Rubraca, Eligard |
| Emd Serono, INC. | $60.40 | 2023-2024 | Bavencio |
| Stemline Therapeutics INC. | $57.32 | 2025 | Orserdu |
| Pharmaand Gmbh | $44.07 | 2025 | Rubraca |
| Kite Pharma, INC. | $41.76 | 2019 | |
| Genmab U.S., INC. | $40.62 | 2023 | Epkinly |
| Springworks Therapeutics, INC. | $40.53 | 2024-2025 | Ogsiveo |
| Sanofi-Aventis U.S. LLC | $37.81 | 2019-2020 | |
| Gilead Sciences, INC. | $36.42 | 2025 | Trodelvy |
| Immunogen, INC. | $33.33 | 2023 | Elahere |
| Kyowa Kirin, INC. | $25.00 | 2024 | Poteligeo |
| Morphosys, US INC. | $24.53 | 2023 | Monjuvi |
| Beone Medicines USA, INC. | $24.53 | 2025 | Brukinsa |
| Spectrum Pharmaceuticals INC. | $18.94 | 2019 | |
| Blueprint Medicines Corporation | $18.51 | 2024 | Ayvakit |
| Shire North American Group INC | $18.25 | 2019 | |
| Telix Pharmaceuticals | $16.32 | 2024 | Illuccix |
| Array Biopharma INC | $16.00 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $15.60 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yelitza Ruiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.